Paper Details

  1. Home
  2. Paper Details

A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.

Author: BarrettAndrew C, BraeckmanRene, BramsMatthew N, CutlerAndrew J, GuentherSven, KollinsScott H, MarraffinoAndrea, MickleTravis C, OhCharles

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Once-daily serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) capsules were found to significantly improve ADHD symptoms in children aged 6-12 compared to placebo, with a rapid onset and extended duration of treatment effect. The treatment was safe, with adverse events comparable to other stimulant treatments.
Paper Details　
Original Abstract of the Article :
<b><i>Objectives:</i></b> To evaluate the efficacy and safety of once-daily serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) capsules (Azstarys<sup>&#8482;</sup>) compared with placebo in children with attention-deficit/hyperactivity disorder (ADHD) in a randomized, double-blind, dose-optimized...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/cap.2021.0077

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of ADHD Treatment

[Attention-deficit/hyperactivity disorder (ADHD)] is a common childhood condition that can significantly impact a child's ability to learn and function effectively. This study explores the potential of [serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH)] capsules, a new type of medication, to offer relief from the symptoms of [ADHD]. The study is like a journey through the desert of [ADHD], searching for a new oasis of treatment options. The study found that [SDX/d-MPH] was effective in improving [ADHD symptoms] in children, offering a potential new option for parents and doctors seeking effective treatment.

SDX/d-MPH's Promise for ADHD Treatment

This study suggests that [SDX/d-MPH] may be a valuable treatment option for children with [ADHD]. The [improvement in ADHD symptoms] observed in the study is significant, highlighting the potential of this medication to help children focus and manage their behavior more effectively.

Hope for a Brighter Future

The findings of this study provide hope for a brighter future for children with [ADHD]. The potential of [SDX/d-MPH] to improve [ADHD symptoms] offers a new approach to treatment, allowing children to reach their full potential.

Dr.Camel's Conclusion

The desert of [ADHD] can be a challenging landscape for children and their families, but this study offers a potential oasis in the form of [SDX/d-MPH]. The findings suggest that this medication may provide a new path to improved focus, behavior, and academic success for children with [ADHD].

Date :
  1. Date Completed 2021-12-10
  2. Date Revised 2021-12-14
Further Info :

Pubmed ID

34714120

DOI: Digital Object Identifier

10.1089/cap.2021.0077

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.